The Psychedelic Therapeutics and Drug Development Conference has been organized to bring together the world’s leading researchers and leaders in academia and industry to discuss the challenges and opportunities facing those engaged in the research and development of psychedelics for various health conditions with considerable unmet need. This event will highlight the progress being made towards regulatory approval of a variety of psychedelics with the potential to treat various conditions, including inflammatory/autoimmune disorders, brain injury, pain, PTSD, anxiety, ADHD, headaches, depression, and opioid use disorder.

• Clinical trial design
• Risk Evaluation & Mitigation Strategy (REMS)
• Abuse potential
• Practical use/indications/
• DEA licensure & policy considerations

• Targets for novel drug development
• Dosage (micro/low/high)
• Second generation psychedelic drug design
• FDA regulatory guidance
• Toxicology studies and considerations